Cryoport Surges with Cell Therapy Growth | Business and Finance News

Cryoport’s Q2 2026 results show explosive growth, with $49M in revenue fueled by a 25% surge in biostorage and bioservices—and a 26% jump in commercial cell and gene therapy support. They now back 70% of global cell and gene therapy trials, including 94 in critical Phase Three, while hitting positive adjusted EBITDA for the first time. New facilities in Paris and Santa Ana, plus AI-driven efficiency gains, are expanding their footprint. With full-year revenue guidance reaffirmed and 11+ regulatory filings on the horizon, Cryoport is cementing its role as the backbone of the next-gen medicine supply chain. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/aca673ad03e9bf15